Skip to Content
Discovering the causes of cancer and the means of prevention

Amy Berrington de González, D.Phil.

Branch Chief and Senior Investigator

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:


Phone: 240-760-6600

Berrington de González Presents at Director’s Seminar

Dr. Berrington de GonzalezWatch Dr. Berrington de González discuss her research at the 2013 NIH Director’s Seminar Series.

Video: Medical radiation and cancer risk: Assessing the price of progress

Amy Berrington de González, D.Phil.

Amy Berrington de González, D.Phil.

Organization:National Cancer Institute
Division of Cancer Epidemiology & Genetics, Radiation Epidemiology Branch
Address:NCI Shady Grove
Room 7E452


Dr. Berrington de González received a D.Phil. in Cancer Epidemiology from the University of Oxford. She was on the faculty at the University of Oxford and then Johns Hopkins Bloomberg School of Public Health before moving to the Radiation Epidemiology Branch at NCI in 2008. She was awarded NIH scientific tenure in 2012, and was promoted to Branch Chief in 2014. Dr. Berrington de González is currently serving on two radiation risk committees for the National Academy of Science and previously served on the UK Health Protection Agency's Advisory Group on Ionising Radiation, and the UK Breast Screening Programme's Advisory Group.

Research Interests

Radiation exposure to the US population from medical sources has increased six-fold in the last three decades. The overarching goal of Dr. Berrington's research is to quantify the potential cancer risks from this important source of radiation exposure in order to provide information for public health and clinical purposes. Her interdisciplinary training in epidemiology and biostatistics allow her to pursue this goal using both theoretical risk projection modeling and also by conducting epidemiological studies of medically exposed populations. The studies vary across the dose-spectrum from low-dose diagnostic and screening procedures to high-dose radiotherapy, with distinct opportunities and challenges in each area.

Diagnostic and screening tests

Dr. Berrington has conducted a series of risk projection studies to estimate the potential cancer risks from both diagnostic and screening examinations, including: cardiac stress tests, CT colonography and lung CT screening. To perform these studies she and other collaborators developed the NCI Radiation Risk Assessment Tool (RadRAT), which is interactive computer software that uses state of the art risk projection models to estimate lifetime cancer risks and incorporates Monte Carlo simulation methods to assess the impact of uncertainties in the assumptions and data. She recently became the NCI Principal Investigator for the UK Pediatric CT scans study, which is a retrospective cohort study of 250,000 children who had one or more CT scans as children or adolescents.

Therapeutic radiation exposure

As cancer treatment and screening has improved markedly the number of patients diagnosed with a second primary cancer has also increased. Studying the second cancer risks after radiotherapy provides both important clinical information and also insights into the long-term effects of high-dose fractionated radiation exposure. Furthermore, as treatments continue to evolve it is important to study the effects of newer treatments on second cancer rates. Dr. Berrington has conducted a number of studies using the SEER cancer registries to evaluate patterns of second cancers and the second cancer risks related to radiotherapy treatment. She is currently developing a cohort of breast cancer survivors using the electronic medical records from Kaiser Permanente Health Plans to study the late effects of various breast cancer treatments. She is also developing methods to project risks from high-doses of radiation exposure and conducting a pilot study to assess the feasibility of performing the first multi-center study of the second cancer risks from proton therapy and IMRT.